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I. INTRODUCTION
In ancient Greek mythos, the gods forbade humankind from having access
to the natural phenomenon of fire. Without fire, the human race was shackled
to a cold and dark existence. An existence bereft of industry, arts, civilization,
and, ultimately, hope. Prometheus rectified this unjust monopoly over nature by
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stealing fire from Zeus and sharing it with all of humanity.1 On March 20,
2012, Mayo Collaborative Services v. Prometheus Laboratories, Inc. (Prome-
theus) seemed to again expand the capabilities of humankind.2 This time the
eponymous savior was a unanimous Supreme Court decision that correctly
reaffirmed that one cannot patent “the underlying laws of nature themselves.”3
When Congress enacted the United States Patent Act in 1952, it specified
that patentable subject matter included anything “under the sun that is made by
man.”4 Three decades ago, the United States Patent and Trademark Office
(USPTO) issued the first gene patent and ushered in a brave new gold rush.5
Some genes are associated with specific diseases, so the ability to identify these
sequences is an essential first step for developing genomic diagnostic tests and
therapies.6 The problem with gene patents is that they allow modern-day pros-
pectors to cordon off access to naturally occurring DNA sequences and exclude
others from conducting research or developing useful applications based on
these sequences.
In 2009, a broad coalition of plaintiffs sued Myriad Genetics Laboratories,
Inc. (Myriad) over its breast cancer gene patents.7 In July 2011, the U.S. Court
of Appeals for the Federal Circuit ruled two to one in favor of upholding Myr-
iad’s gene patents in Association for Molecular Pathology v. U.S. Patent &
Trademark Office (Myriad).8 Subsequently, on March 26, 2012, the Supreme
Court vacated the Myriad decision and remanded it back to the Federal Circuit
for reconsideration in light of its ruling in Prometheus.9 However, in Associa-
tion for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad II), a
two to one majority in the Federal Circuit misapplied the Supreme Court’s
directive and upheld Myriad’s composition claims covering isolated DNA
sequences of the BRCA 1/2 breast cancer genes and complementary DNA
(cDNA) sequences of BRCA that nature predetermined.10
1 The gods punished Prometheus by binding him to a rock with chains and having an eagle
eat out his liver every day. As an immortal Titan, his liver regenerated every night and this
torture repeated in perpetuity. Eventually, mankind repays its debt when Hercules unbinds
Prometheus.
2 Mayo Collaborative Servs. v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012).
3 See id. at 1305.
4 Jonah D. Jackson, Note, Something Like the Sun: Why Even “Isolated and Purified”
Genes Are Still Products of Nature, 89 TEX. L. REV. 1453, 1454 (2011) (quoting S. REP. NO.
82-1979, at 5 (1952); H.R. REP. NO. 82-1923, at 6 (1952)) (internal quotation marks
omitted).
5 See Gene Patents and Global Competition Issues, 26 GEN: GENETIC ENGINEERING & BIO-
TECHNOLOGY NEWS (Jan. 1, 2006), http://www.genengnews.com/gen-articles/gene-patents-
and-global-competition-issues/1163/.
6 See Fact Sheet: BRCA1 and BRCA2: Cancer Risk and Genetic Testing, NAT’L CANCER
INST. (May 29, 2009), http://www.cancer.gov/cancertopics/factsheet/risk/brca [hereinafter
NAT’L CANCER INST.] (explaining, for example, that humans who inherit a harmful BRCA1
or BRCA2 mutation are at a higher risk of developing breast cancer).
7 Complaint at 1, Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 669 F.
Supp. 2d 365 (S.D.N.Y. May 12, 2009) (No. 09-cv-04515-RWS), 2009 WL 1343027.
8 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed.
Cir. 2011), vacated, appeal reinstated, 467 Fed. Appx. 890 (Fed. Cir. 2012).
9 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012).
10 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303, 1337
(Fed. Cir. 2012).
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Myriad is now back in the Supreme Court as oral arguments were heard
on April 15, 2013.11 While there have been mixed opinions as to whether gene
patents were dead in light of Prometheus,12 this Article argues that a proper
understanding of patent law, genomics, and public policy concerns should lead
to no other result. The primary focus of this piece is to rebut certain vested
interests in the biotechnology industry and affirm the normative claim that gene
patents improperly fetter genomics research and development. First, through
the lens of the Myriad case, we will recount why there was such a strong public
interest movement against recognizing such patents. Specifically, we will show
how patents on naturally occurring gene sequences and complementary DNA
(cDNA) derived from these sequences stifle research, impede access to afforda-
ble testing, and detrimentally affect future developments in the cancer world.
Second, we will briefly examine the Supreme Court’s legal reasoning in Pro-
metheus and how the Federal Circuit did not address the Court’s concerns on
remand. Finally, we will argue that, in order to significantly advance, the field
of genomics needs freedom from ill-considered monopolies over naturally
occurring DNA sequences as much as the ancients needed fire.
II. WHAT IS “NATURAL” IN GENOMICS? UNDERSTANDING THE SCIENCE TO
ARRIVE AT THE PROPER LEGAL STANDARD
Since 2009, the American Civil Liberties Union (ACLU) has led the fight
against Myriad and its strict enforcement of the BRCA1 and BRCA2 (BRCA1/
2) patents.13 Almost twenty percent of human genes are patented, including
those associated with Alzheimer’s disease, asthma, colon cancer, muscular dys-
trophy, and breast and ovarian cancer.14 The USPTO, also a party-defendant in
Myriad, grants these patents and gives the holders exclusive rights to the partic-
ular genetic sequences and their usage for twenty years.15 By controlling the
sequence to BRCA1/2, “Myriad also controls exclusive rights to mutations
along those genes, any methods for locating mutations (whether those methods
are currently known or not), and correlations between mutations and breast
cancer.”16 In other words, Myriad has the right to prevent anyone else from
testing, studying, or even looking at these genes.
The ACLU and joined co-parties contend that gene patents “undermine the
free exchange of information and scientific freedom, bodily integrity, and
women’s health.”17 Their argument is that the contested gene patents create a
11 Transcript of Oral Argument at 1, Ass’n for Molecular Pathology v. Myriad Genetics,
Inc., 132 S. Ct. 1794 (2012) (No. 12–398), available at http://www.supremecourt.gov/oral_
arguments/argument_transcripts/12-398-amc7.pdf.
12 See, e.g., Andrew Pollack, Justices Send Back Gene Case, N.Y. TIMES, Mar. 27, 2012, at
B1.
13 FAQ: Legal Challenge to Patenting of Human Genes, ACLU (Sept. 10, 2010), http://
www.aclu.org/files/assets/legal_faq_brca.pdf [hereinafter ACLU FAQ].
14 Id.
15 Id.
16 Id.
17 Ann Weilbaecher, Can Patent Protections Trample Civil Liberties? The ACLU Chal-
lenges the Patentability of Breast Cancer Genes, 15 LOY. PUB. INT. L. REP. 10, 10 (2009)
(quoting AMERICAN CIVIL LIBERTIES UNION, LEGAL CHALLENGE TO HUMAN GENE PATENTS
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dangerous monopoly that restricts health care options for women, obstructs
diagnostic testing, and stifles research.18 Myriad, and its supporters in the bio-
technology industry, allege that without intellectual property protection, com-
panies will not invest the millions of dollars necessary to validate genetic tests.
Myriad supporters also argue that this would work contrary to the original
intent of the patent system, which was designed as a way to incentivize
research and reward companies for their inventions.19
The breadth of amicus briefs filed in favor of the ACLU’s position by
professional medical societies, researchers, and cancer-afflicted individuals is
very telling and demonstrates the outmoded and counter-normative analysis of
the Court of Appeals of the Federal Circuit.20 Essentially, the Federal Circuit
validated patents for isolated DNA molecules and Myriad’s BRCA1/2 genes,
which vested interests within the biotechnology and pharma industries consid-
ered a victory.21
The direct consequence of upholding Myriad’s patents was to ultimately
redirect the standard of care for breast cancer testing.22 Further, this appellate
decision naturally caused great concern within the diagnostic field23 and among
those who are personally vested and impacted by the case. In the words of
presiding Judge Sweet of the District Court:
The challenges to the patents-in-suit raise questions of difficult legal dimensions con-
cerning constitutional protections over the information that serves as our genetic
identities and the need to adopt policies that promote scientific innovation in
biomedical research. The widespread use of gene sequence information as the foun-
dation for biomedical research means that resolution of these issues will have far-
reaching implications, not only for gene-based health care and the health of millions
of women facing the specter of breast cancer, but also for the future course of
biomedical research.24
A. Who “Owns” Breast Cancer Genes?
I am a business owner, artist and writer and I live in Austin, Texas. I was diag-
nosed with breast cancer in July of 2006 at age 36 and I had a double
mastectomy. . . .
5 (May 27, 2009), http://www.aclu.org/pdfs/freespeech/brca_qanda.pdf) (internal quotation
marks omitted).
18 Id. at 10–11.
19 Id. at 11.
20 See Jennifer A. Camacho, Myriad and the Patent-Eligibility of Genetic Inventions:
What’s the Matter Under 35 U.S.C. § 101?, 23 INTELL. PROP. & TECH. L.J. 10, 10, 12–16
(2011) (discussing the Federal Circuit’s analysis).
21 Id. at 10.
22 See Declaration of Shobita Parthasarathy at ¶ 31, Ass’n for Molecular Pathology v. U.S.
Patent & Trademark Office, 669 F. Supp. 2d 365 (S.D.N.Y. 2009) (No. 09 Civ. 4515
(RWS)), available at http://www.aclu.org/files/pdfs/freespeech/brca_Parthasarathy_declara-
tion_20090826.pdf [hereinafter Declaration of Shobita Parthasarathy].
23 See Jackie Wright Bonilla, Highly Anticipated “ACLU/Myriad” Gene Patenting Case
Decided by Federal Circuit, PERSONALIZED MED. BULL. (July 29, 2011), http://www.person-
alizedmedicinebulletin.com/2011/07/29/highly-anticipated-aclumyriad-gene-patenting-case-
decided-by-federal-circuit-subject-matter-paten/.
24 Order Denying Defendant’s Motion to Dismiss at 2–3, Ass’n for Molecular Pathology v.
U.S. Patent & Trademark Office, 669 F. Supp. 2d 365 (S.D.N.Y. 2009) (No. 09 Civ. 4515).
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When I was confronted with this alien invasion (cancer), I decided to be as
aggressive as I could to prevent the potential spread. I also decided to be diligent
about getting second opinions along the treatment path. In one important area, how-
ever, I couldn’t follow my second opinion treatment protocol . . . .
. . . .
Because of patents on the BRCA genes, only one company out there has the
ability to sequence them. I can’t get a second sequencing done at a different company
to validate my results. I am thinking about having my ovaries removed because of
my risk for ovarian cancer. It is uncomfortable making such an important decision
based on only one test.25
For the 12% of women who develop breast cancer in their lifetime, and the
1.4% of women who develop ovarian cancer,26 prior knowledge of an inherited
mutation makes the difference between life and death. “BRCA1 and BRCA2
are two human genes . . . associated with hereditary forms of breast and ovarian
cancer,” and, though everyone has these genes, mutations sometimes occur.27
When they do, these individuals have an “elevated lifetime risk” of developing
cancer.28 In fact, studies have shown that a woman who inherits a harmful
mutation in BRCA1/2 “is about five times more likely to develop breast cancer
than a woman who does not have such a mutation.”29 Harmful BRCA1/2 muta-
tions are also associated with breast and prostate cancer in men.30
Research indicates that individuals who test positive for BRCA1/2 gene
mutations face an increased risk of breast cancer ranging from 40% to 85% and
an increased risk of ovarian cancer of 15% to 40%.31 Statistics from 2007
revealed that the relative lifetime risk of breast cancer was 2.7 to 6.4 times
greater for those with BRCA mutations, and for ovarian cancer it was 9.3 to
35.3 times greater compared with other women.32
Myriad Genetics is a private biotechnology company based in Utah.33 The
company’s research helped develop the BRCA1/2 patents, supported in part by
grants from the National Institutes of Health (NIH).34 In December of 1995,
Myriad Genetics filed for patents of its “BRACAnalysis,” which consists of a
full analysis of the BRCA1/2 genes and detects five common mutations.35
Although NIH investigators are listed as co-inventors, they assign the adminis-
tration of the BRCA1/2 patents to the University of Utah with exclusive licens-
25 Genae Girard, BRCA—Plaintiff Statements, AMERICAN CIVIL LIBERTIES UNION (May 12,
2009), http://www.aclu.org/free-speech_womens-rights/brca-plaintiff-statements#girard
[hereinafter Girard, Plaintiff Statement].
26 NAT’L CANCER INST., supra note 6, at ¶ 2.
27 See ACLU FAQ, supra note 13.
28 Id.
29 NAT’L CANCER INST., supra note 6, at ¶ 2.
30 ACLU FAQ, supra note 13.
31 Weilbaecher, supra note 17, at 11.
32 Robert Cook-Deegan et al., Impact of Gene Patents and Licensing Practices on Access to
Genetic Testing for Inherited Susceptibility to Cancer: Comparing Breast and Ovarian Can-
cers with Colon Cancers, 12 GENETICS MED. S15, S19–S20 (Apr. 2010 Supp.).
33 ACLU FAQ, supra note 13.
34 Cook-Deegan et al., supra note 32, at S20.
35 Suzanne Conaboy, Note, Mirror, Mirror on the Wall: Why cDNA Is Deserving of Patent
Protection Ass’n for Molecular Pathology v. USPTO, 2010 U.S. Dist. LEXIS 35418
(S.D.N.Y. Apr. 2, 2010), 30 TEMP. J. SCI., TECH. & ENVTL. L. 111, 125 (2011).
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ing to Myriad Genetics.36 The patents are co-assigned to the University of Utah
and United States Department of Health and Human Services, but Myriad
Genetics effectively controls the patent rights. Myriad’s patent rights extend to
both the BRCA1/2 genes and the accompanying tests.37 “If Myriad had simply
patented a test, then other scientists and laboratories could offer alternative test-
ing on these genes.”38 Instead, Myriad’s power extends to all research, testing,
and future developments involving the BRCA genes.39
B. Misreading Precedent: Why Gene Sequences Fail the Patentability Test
The founder of Myriad Genetics, Dr. Mark Skolnick, has a strong belief
that his company earned the patents because of the large financial investment
involved in obtaining them.40 He further claims that Myriad Genetics obtained
the “right” to administer these tests. Myriad receives approximately 350 new
samples per day.41 Each analyzed sample undergoes one or both of the two
tests Myriad performs: the Comprehensive BRACAnalysis test and an addi-
tional expanded BRACAnalysis Rearrangement Test (BART), which detects
large rearrangement mutations.42 According to Dr. Skolnick, “no women would
have been tested for the BRCA mutations if not for Myriad.”43 Further, patent
protection incentives established the reason for Myriad Genetics’ inception
“because the necessary funding would not have been made available by
investors.”44
To meet eligibility requirements for a patent in the United States, the
USPTO must certify that the invention meets three separate conditions: (1)
novelty, (2) utility, and (3) nonobviousness.45 When it comes to biological
material, whether genetic or not, much controversy surrounds the patent eligi-
bility of those “inventions” naturally occurring in humans. When the Patent Act
was enacted in 1952, it applied to any subject matter “under the sun that is
made by man.”46 Later, this assertion was modified by the “product of nature”
doctrine, which prohibits patents based on the “laws of nature, physical phe-
nomena, and abstract ideas” and mental processes.47 These three exceptions to
patent eligibility came from a 1980 United States Supreme Court case, Dia-
mond v. Chakrabarty, which is the first and only decision directly addressing
the patentability of living organisms.48 The Court in Chakrabarty upheld a
36 Cook-Deegan et al., supra note 32, at S20.
37 Id.
38 ACLU FAQ, supra note 13.
39 Id.
40 Marisa Noelle Pins, Note, Impeding Access to Quality Patient Care and Patient Rights:
How Myriad Genetics’ Gene Patents Are Unknowingly Killing Cancer Patients and How to
Calm the Ripple Effect, 17 J. INTELL. PROP. L. 377, 381–82 (2010).
41 Id. at 382.
42 Conaboy, supra note 35, at 125.
43 Pins, supra note 40, at 382.
44 Id.
45 Id. at 385.
46 Jackson, supra note 4, at 1454 (quoting S. REP. NO. 82-1979, at 5 (1952); H.R. REP. NO.
82-1923, at 6 (1952)).
47 Id. (quoting Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
48 Chakrabarty, 447 U.S. at 309.
\\jciprod01\productn\N\NVJ\13-3\NVJ303.txt unknown Seq: 7 12-JUN-13 13:06
674 NEVADA LAW JOURNAL [Vol. 13:668
“patent for a laboratory-created bacterium with properties not found in
nature.”49 Two years later, the USPTO granted its first human genetic material
patent.50
The patent system originally granted “certain rights to inventors for their
inventions in order to reward and encourage human ingenuity.”51 But, as the
ACLU correctly argues, genes are not inventions but, rather, natural parts of the
human body. In fact, the USPTO recognizes this differentiation by maintaining
the Chakrabarty exception: that products of nature are not patentable.52
Reflecting a lack of familiarity with genomics, for the past three decades the
USPTO has stated that genetic sequence may qualify as patentable material if it
is “isolated and purified” by removing the gene from the human body and strip-
ping away its “non-coding regions.”53 However, this isolation and purification
process as applied to human genes is “simple enough for any graduate student
in genetics or a related field to perform.”54 Therefore, the BRCA1/2 patenting
process is properly analogized as if one mined (i.e., “isolated”) gold from a
mountain and then patented the gold,55 therefore violating the novelty and non-
obviousness requirements for patentable material.
Consequently, the ACLU and twenty others initiated a lawsuit against
Myriad Genetics on May 12, 2009, officially challenging the BRCA1/2 gene
patents. Generally, the plaintiffs attacked patents on: (1) natural human genes,
(2) genes with natural mutations, (3) any method of looking for mutations in
natural human genes, and (4) the concept that individual gene variants are dif-
ferent and have specific effects, which “correlate with an increased risk of
breast and/or ovarian cancer.”56 On March 29, 2010, the district court granted
the plaintiffs’ motion for summary judgment, effectively declaring Myriad’s
patents invalid based on the theory that they contain products of nature and
abstract ideas.57 Shortly after, the defendants appealed.58
On July 29, 2011, the appellate court found for Myriad Genetics, reversing
in part the prior decision.59 In the majority opinion, the court first held that
isolated DNA does not stem from products of nature, and therefore is patent-
eligible.60 The court held valid Myriad’s “growing” and “determining” method
for screening potential cancer therapeutics.61 However, the “comparing” or
“analyzing” diagnostic methods used on DNA sequences were not patent-eligi-
49 Jackson, supra note 4, at 1454.
50 Id.
51 ACLU FAQ, supra note 13.
52 Id.
53 Id.
54 Id.
55 Id.
56 Pins, supra note 40, at 380–81 (quoting Complaint at 15, Ass’n for Molecular Pathology
v. U.S. Patent & Trademark Office, No. 09 Civ. 4515 (S.D.N.Y. May 12, 2009), 2009 WL
1343027).
57 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181,
185–86 (S.D.N.Y. 2010).
58 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 1333
(Fed. Cir. 2011).
59 Id. at 1329, 1333.
60 Id. at 1350.
61 Id. at 1357.
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ble because they involve abstract mental processes.62 Jim Greenwood, the Pres-
ident and CEO of co-defendant Biotechnology Industry Organization (BIO),
released a statement directly following Myriad’s “win.”63 Reiterating the pat-
entability of gene processes, he said, “patented DNA molecules have been put
to countless uses that have benefited society. . . . [T]hey are fundamentally
different from anything that occurs in nature.”64 Yet the court’s decision
regarding the products of nature doctrine was close at two to one, with a strong
dissent.65
C. Ruling in Prometheus Should Invalidate Patents on Isolated Gene
Sequences and Complementary DNA (cDNA)
Only months after the Supreme Court granted certiorari to Myriad, the
Court ruled a blood-test patent developed by Prometheus invalid, reinforcing
the “law of nature” doctrine.66 The test at issue examined the chemical reaction
of a prescription drug, directing a doctor to modify the dosage and make the
treatment more effective or avoid unwanted side effects based upon measured
metabolite levels within the patient.67 In a unanimous decision, Justice Breyer
wrote that inventors must do more than “recite a law of nature and then add the
instruction ‘apply the law.’ ”68 Thus, the Court highlighted that invention
requires going beyond merely describing what nature has already
predetermined.
The laws of nature involved here are the “relationships between concentrations of
certain metabolites in the blood and the likelihood that a dosage of a thiopurine drug
will prove ineffective or cause harm.” The legal question then becomes, “do the
patent claims add enough to their statements of the correlations to allow the
processes they describe to qualify as patent-eligible processes that apply natural
laws?” For all nine members of the Court, the answer was a clear no.69
Subsequently, the Court vacated the Myriad decision and remanded it back to
the Federal Circuit for reconsideration in light of its ruling in Prometheus.70
On remand, in addition to ruling on several method claims, a two to one
majority upheld Myriad’s composition claims covering both i) isolated BRCA
62 Id. at 1355.
63 See Pins, supra note 40, at 396.
64 Id. (quoting Press Release, Biotechnology Industry Organization, BIO Statement on Ini-
tial Decision in Myriad Genetics Lawsuit (Mar. 30, 2010), available at http://www.bio.org/
media/press-release/bio-statement-initial-decision-myriad-genetics-lawsuit).
65 John Conley, ACLU and Myriad Both Seek Further Federal Circuit Review, GENOMICS
L. REP. (Sept. 2, 2011), http://www.genomicslawreport.com/index.php/2011/09/02/aclu-and-
myriad-both-seek-further-federal-circuit-review.
66 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1305 (2012).
67 Id. at 1295.
68 Id. at 1297.
69 John Conley & Allison Williams Dobson, Prometheus Patents Struck Down, 9-0: Mayo
Collaborative Services v. Prometheus Laboratories, Inc. Analysis, GENOMICS L. REP. (Mar.
21, 2012), http://www.genomicslawreport.com/index.php/2012/03/21/prometheus-patents-
struck-down-9-0-mayo-collaborative-services-v-prometheus-laboratories-inc-analysis/#
more-6594.
70 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012).
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sequences and ii) cDNA sequences derived from such isolated sequences.71
Focusing on these composition claims, it is clear that the Federal Circuit
reached its conclusions based upon erroneous scientific assumptions regarding
isolated DNA sequences and unfamiliarity with natural laws that predetermine
how complementary DNA is formed given a naturally occurring predicate
strand of mRNA. These scientific misconceptions are material as a matter of
patent law because they relate to the threshold issue of patent eligibility under
Section 101. As illustrated below, the Federal Circuit incorrectly applied the
threshold tests of “markedly different” from Chakrabarty and “law of nature”
from Prometheus.
i. Isolated DNA Sequences Are Not “Markedly Different” from What
Exists in Nature
As Judge Bryson noted in his dissent, the Chakrabarty test “requires us to
focus on two things: (1) the similarity in structure between what is claimed and
what is found in nature and (2) the similarity in utility between what is claimed
and what is found in nature.”72 Applying this test, Bryson correctly reasoned
that isolated gene sequences should not be patent eligible as “extracting a gene
is akin to snapping a leaf from a tree . . . [a] human kidney is a product of
nature; it does not become a patentable invention when it is removed from the
body, even if the patentee has developed an improved procedure for extracting
the kidney.”73 The majority rejected this characterization based on the empiri-
cally false assumption that isolated DNA sequences are unique molecules that
do not exist absent human actions:
In this case, the claimed isolated DNA molecules do not exist in nature . . . . They
have to be chemically cleaved from their native chemical combination . . . . In other
words, in nature, the claimed isolated DNAs are covalently bonded to such other
materials. Thus, when cleaved, an isolated DNA molecule is not a purified form of a
natural material, but a distinct chemical entity that is obtained by human
intervention.74
However, as the renowned geneticist Dr. Eric Lander explains in his
Supreme Court amicus brief, it has been empirically “established for over 30
years that isolated DNA fragments of human chromosomes routinely occur in
the human body.”75 These isolated DNA fragments (which typically arise after
a cell dies) with their cleaved covalent bonds at the ends of the fragments, are
not chemically distinct in their composition from the type of isolated DNA
claimed by Myriad.76 More specifically, “these isolated DNA fragments span
the entire human genome, including the BRCA1 and BRCA2 genes.”77 This
means that it is certain that isolated sequences of the BRCA gene exist in nature
71 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303, 1337
(Fed. Cir. 2012).
72 Id. at 1354 (Bryson, J., dissenting).
73 Id. at 1352 (Bryson, J., dissenting).
74 Id. at 1325, 1329.
75 Brief for Amicus Curiae Eric S. Lander in Support of Neither Party at 12, Ass’n for
Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012) (No. 12–398).
76 Id. at 17.
77 Id. at 12.
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and that Myriad’s composition claims cover these naturally occurring
sequences as it claims isolated BRCA sequences 15 nucleotide bases or
longer.78 Thus, since Myriad’s composition patent claims cover molecules that
already exist in nature, these claims obviously fail the “markedly different”
threshold.
During oral arguments on Myriad II in April 2013, Myriad’s attorney,
Gregory Castanias, essentially conceded that Myriad’s composition claims on
BRCA 1/2 were justified, not because of substantive physical differences from
what existed in nature, but merely because Myriad articulated a use (diagnosis
of breast cancer risk) that was different from its natural function (coding for a
protein).79 Interrogating the consequence of this logic, Justice Kagan inquired
whether “the first person who isolated chromosomes could have gotten a patent
on that?”80 Being logically consistent but wrong on the law, Castanias replied
that under Myriad’s theory an isolated chromosome would be patent eligible
under Section 101: “if that chromosome had a specific substantial and credible
utility, in other words, it could be used in some . . . diagnostic way in the way
that we’re talking about here, then yes, it would pass through the Section 101
gate.”81 As Justice Kagan alertly noted, the above statement is an admission by
Myriad that the supposed differences in chemical structure between isolated
DNA and chromosomal DNA are irrelevant for its patent eligibility theory,
“[a]nd that’s interesting . . . because then it’s not a question about, you know,
breaking these covalent bonds or whatever Judge Lourie thought it was
about.”82 Furthermore, Myriad’s argument is again wrong on the science,
because it is based on the erroneous assumption that isolated chromosomes can
serve no diagnostic purpose. Of course, as any doctor or older couple that is
planning a pregnancy can tell you, the presence of an extra chromosome 21 in a
pregnant woman’s blood indicates that her fetus has trisomy 21, which is diag-
nostic for Down syndrome. Thus, if we accept Myriad’s logic, Dr. Jerome
Lejeune could have filed a patent for the third copy of chromosome 21 when he
associated its presence with Down syndrome.83
ii. The Synthesis of cDNA Results from a “Law of Nature”
Complementary DNA (cDNA) composition claims should not be patent
eligible because the laws of nature predetermine their sequence and function.
First, we will explain what cDNA is and why it does not pass the “law of
nature” patent eligibility test. Second, we will distinguish cDNA from DNA
probes, primers, and recombinant DNA, all of which should be considered pat-
ent eligible because their sequence and functions are not predetermined by
nature.
78 See id. at 17.
79 Transcript of Oral Argument at 40, Ass’n for Molecular Pathology v. Myriad Genetics,
Inc., 132 S. Ct. 1794 (2012) (No. 12–398).
80 Id. at 52.
81 Id. at 53–54.
82 Id. at 54.
83 Discovering Trisomy 21, JEROMELEJEUNE.ORG, http://jeromelejeune.org/the-scientist/dis-
covering-trisomy-21.html (last visited May 15, 2013).
\\jciprod01\productn\N\NVJ\13-3\NVJ303.txt unknown Seq: 11 12-JUN-13 13:06
678 NEVADA LAW JOURNAL [Vol. 13:668
As explained in Myriad II, most human genes contain both exon and
intron sequences: “Exons are DNA segments that are necessary for the creation
of a protein . . . . Introns are segments of DNA interspersed between the exons
that, unlike exons, do not code for a protein.”84 In order to create a protein from
this DNA sequence, it first has to be transcribed into RNA.85 During transcrip-
tion, “the DNA double helix is unwound and each nucleotide on the non-cod-
ing, or template, DNA strand is used to make a complementary, single-stranded
RNA molecule that mirrors the coding DNA strand.”86 However, the resulting
“pre-RNA” strand cannot be directly translated into a protein because it still
contains the non-coding intron sequences.87 What happens next is that “the
introns are physically excised from the pre-RNA molecule, followed by “splic-
ing” the exons to produce a messenger RNA (“mRNA”).”88 It is only after
transcription and splicing that the resulting mRNA can be translated into a pro-
tein.89 Using this naturally occurring mRNA: “cDNA is synthesized . . . using
complementary base pairing in a manner analogous to RNA transcription. The
process results in a double-stranded DNA molecule with a sequence corre-
sponding to the sequence of an mRNA produced by the body.”90 Since the
cDNA is synthesized from mRNA, it only contains exon sequences which dif-
ferentiates it from the chromosomal gene sequence which contains both exons
and introns.91
From the simple description above, one might conclude that cDNA should
be patent eligible because it does not occur naturally within the body. However,
as the majority opinion in Myriad II acknowledges, the cDNA claimed by Myr-
iad is not produced by some novel process, but rather by “complementary base
pairing in a manner analogous to RNA transcription.”92 In other words, the
cDNA is produced using a law of nature that evolution, not Myriad, fashioned.
Further, the exact sequence is also predetermined by evolution as the majority
opinion notes that the resultant cDNA is “a sequence corresponding to the
sequence of an mRNA produced by the body.”93
In Chakrabarty, the patentable invention was an oil-degrading bacteria
“genetically engineered with four naturally occurring DNA plasmids.”94 Plas-
mids are small DNA molecules that are “physically separate from, and can
replicate independently of, chromosomal DNA within a cell.”95 From
Chakrabarty, it is clear that the four naturally occurring DNA plasmids would
not be patent eligible on their own––they are obviously products of nature.
84 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad II), 689 F.3d
1303, 1311 (Fed. Cir. 2012).
85 Id.
86 Id.
87 Id.
88 Id.
89 Id. at 1312.
90 Id. at 1313.
91 Id. at 1313–14.
92 Id. at 1313 (emphasis added).
93 Id. at 1313 (emphasis added).
94 Id. at 1327.
95 Plasmids: General Principles, BOUNDLESS, https://www.boundless.com/microbiology/
microbial-genetics/plasmids/plasmids-general-principles/ (last visited May 16, 2013).
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However, the process of inserting these products of nature into a microorga-
nism that did not previously contain them, transformed the bacteria into some-
thing that had “markedly different characteristics from any found in nature.”96
In contrast, in Funk Brothers, the Court ruled that a mix of naturally occurring
bacteria strains that had cooperative nitrogen-fixing qualities was not patenta-
ble since the underlying process was “the work of nature.”97 As the Federal
Circuit reasoned, “applying the newly discovered bacterial compatibility to cre-
ate a mixed culture was not a patentable advance because no species acquired a
different property or use.”98
The cDNA claimed by Myriad is analogous to the naturally occurring
DNA plasmids in Chakrabarty and bacteria cultures in Funk Brothers. On its
own the cDNA codes for proteins already found in nature and the exact
sequence of protein-encoding cDNA has already been pre-determined by
nature, not the putative inventors. Under the logic of Chakrabarty, cDNA only
seems to be patentable as a component of some larger composition that was
“markedly different” from what existed in nature, which brings us to recombi-
nant DNA technology.
The importance of cDNA is that it can be used as a building block
sequence to create recombinant DNA (“rDNA”) sequences that code for human
proteins such as insulin. In other words, cDNA has no therapeutic value unless
something more is added to it. Recombinant DNA technology is a process that
“uses enzymes to cut and paste together DNA sequences of interest.”99 For
example, one could make rDNA that consisted of the cDNA and splice it
together with the appropriate DNA sequences that code for mRNA that can be
used by the host organism’s (e.g., bacteria) translational apparatus. Making
rDNA using an isolated human gene sequence instead of the corresponding
cDNA would not work in the above scenario as bacteria (and all prokaryotes)
lack the splicing mechanism to remove the non-coding introns (see description
of transcription and splicing above). cDNA solves this problem because it is
“pre-spliced.” Transcription of cDNA within bacteria thus results in mRNA
that can then be translated into human protein.
Clearly rDNA should be patentable because not only do such sequences
not exist in nature, but in addition their sequences are not predetermined by any
law of nature.100 rDNA creation is an art that requires cutting, pasting, and
96 Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980).
97 Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).
98 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad II), 689 F.3d
1303, 1327 (Fed. Cir. 2012).
99 Recombinant DNA (rDNA), GENOME.GOV, http://www.genome.gov/glossary/index.cfm?
id=173 (last visited May 16, 2013).
100 By the same logic, DNA probes and primers should be patent-eligible because their
sequence and functions are not predetermined by nature. See Probe, GENOME.GOV, http://
www.genome.gov/glossary/index.cfm?id=165 (last visited May 16, 2013) (“A probe is a sin-
gle-stranded sequence of DNA or RNA used to search for its complementary sequence in a
sample genome. The probe is placed into contact with the sample under conditions that allow
the probe sequence to hybridize with its complementary sequence. The probe is labeled with
a radioactive or chemical tag that allows its binding to be visualized. In a similar way,
labeled antibodies are used to probe a sample for the presence of a specific protein.”); Pri-
mer, GENOME.GOV, http://www.genome.gov/glossary/index.cfm?id=163 (last visited May
16, 2013) (“A primer is a short, single-stranded DNA sequence used in the polymerase chain
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recombining DNA sequences in the correct order to make these sequences
operational in their host organisms. Thus, starting with the same cDNA build-
ing block, multiple parties can make differing (and all patentable) rDNA
sequences that code for the same human protein but that perhaps use different
hosts (e.g., yeast instead of bacteria) or result in higher or more pure yields of
the desired protein product. Allowing a monopoly on the underlying and natu-
rally predetermined cDNA sequence would block innovation in the recombi-
nant DNA marketplace.
III. THE HARMFUL MEDICAL AND ECONOMIC IMPACTS OF
MYRIAD’S GENE MONOPOLY
I’m a 41-year-old mother of two . . . . Both my mother and maternal grandmother
died from breast cancer. I’m worried about having a genetic predisposition for cancer
but haven’t been able to afford an additional test that would give me information
about my genes. . . .
. . . .
Since childhood I have worried about cancer. This test would give me informa-
tion I need to make life-changing medical decisions. There are so many unknowns.
Why did my mother and her mother die from breast cancer? . . .
I keep thinking about the legacy of motherless children in my family. From
breast cancer, my mother died when she was only 28; my grandmother, at 52. My
great grandmother (maternal grandmother’s mother) died from the influenza at 33. I
really want to be here for my kids. It is important for me to make informed decisions
about my health. . . .
If I learned that I definitely inherited a genetic link to cancer, it would signifi-
cantly change how I would protect my health.101
The Myriad case attracted a large amount of media attention and the law-
suit evoked a variety of challenges. From genetic counselors to cancer patients,
and researchers to corporate directors, multiple arguments developed for and
against patenting BRCA1/2. It would be impossible to encompass the breadth
and depth of perspectives that take issue with human gene patenting, but it is
necessary to delve into a few in order to understand the impact of the Myriad
case. Some entities focus on the damaging consequences resulting from Myr-
iad’s monopoly and patent exclusivity. Others, like the ACLU, see gene patent-
ing as a constitutional issue that infringes upon First Amendment rights.102
Ultimately, many agree that the patients are the ones who are eventually
harmed, as BRCA1/2 tests are expensive and insurance does not always cover
the costs.
A. Gene Patents Lock Down Innovation
Myriad Genetics’ strict enforcement of its license creates a monopoly in
the field. Using its patent power, Myriad has sent several cease-and-desist let-
reaction (PCR) technique. In the PCR method, a pair of primers is used to hybridize with the
sample DNA and define the region of the DNA that will be amplified. Primers are also
referred to as oligonucleotides.”).
101 Kathleen Raker, BRCA—Plaintiff Statements, AMERICAN CIVIL LIBERTIES UNION (May
12, 2009), http://www.aclu.org/free-speech_womens-rights/brca-plaintiff-statements#raker.
102 ACLU FAQ, supra note 13.
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ters to laboratories and researchers throughout the United States, ordering them
to stop testing on BRCA1/2 genes.103 Out of fear of patent infringement penal-
ties, this resulted in a chilling effect among the various parties who deal with
diagnostic testing. Dr. Harry Ostrer, a professor of pediatrics, pathology, and
medicine, and a plaintiff in the case,104 is a working example of this fear that
many are experiencing. Dr. Ostrer was unable to provide patients with results
of BRCA1/2 tests due to Myriad’s patents, something he desired to do, and
testified that he would do if the patents were invalidated.105 Dr. Ostrer dis-
played frustration with the BRCA1/2 patents as they currently stand:
Currently, I am recruiting hundreds of women into a new study to identify other
genes associated with a risk of breast cancer. . . . Unfortunately, once such new genes
are identified, the use of this information in clinical practice could be limited because
it might be viewed by Myriad Genetics as infringing on its BRCA patents.
. . . .
Every day I think about how the findings of the research laboratory can be
translated into new genetic tests that might benefit, not harm, people.106
In 2010, Myriad Genetics brought in $353 million (eighty-eight percent of
their total revenue) from the breast cancer tests.107 However, the industry has
not seen any innovations from Myriad in the past five years, when it last intro-
duced the most recent BRCA1/2 test.108 Executives at Myriad say they plan to
prepare for technological improvements in response to claims of newer DNA-
sequencing techniques being faster and less expensive compared to the technol-
ogy Myriad uses, which is reportedly from the 1990s.109 Former Myriad
employee Sean Tavtigian admitted that the company “is trying to catch up, but
‘it’s kind of slow going.’ ”110
In fact, Life Technologies has developed a new Proton Sequencer that can
read a person’s entire genome for $1,000,111 much less than Myriad charges for
its two-gene test. A British company, Oxford Nanopore, recently introduced the
world’s first miniature DNA sequencer that will be available commercially this
year for $900.112 But, because of strict patent protection on BRCA1/2, lawyers
103 Id.
104 Declaration of Harry Ostrer at ¶ 1, Ass’n for Molecular Pathology v. U.S. Patent &
Trademark Office, 669 F. Supp. 2d 365 (S.D.N.Y. 2009) (No. 09-4515), available at http://
www.aclu.org/files/pdfs/freespeech/brca_Ostrer_declaration_20090826.pdf.
105 Id. at ¶¶ 4, 8.
106 Harry Ostrer, M.D., BRCA—Plaintiff Statements, AMERICAN CIVIL LIBERTIES UNION
(May 12, 2009), http://www.aclu.org/free-speech_womens-rights/brca-plaintiff-statements#
ostrer [hereinafter Ostrer, Plaintiff Statement].
107 Andrew Pollack, Despite Gene Patent Victory, Myriad Genetics Faces Challenges, N.Y.
TIMES (Aug. 24, 2011), http://www.nytimes.com/2011/08/25/business/despite-gene-patent-
victory-myriad-genetics-faces-challenges.html?pagewanted=all.
108 Ostrer, Plaintiff Statement, supra note 106.
109 See Pollack, supra note 107.
110 Id.
111 Clive Cookson, Machine to Read Individual’s DNA for $1,000, FIN. TIMES (Jan. 10,
2012, 5:06 AM), http://www.ft.com/intl/cms/s/2/e3c6b7bc-3ac3-11e1-a75600144feabdc0.
html%23axzz1maUoc31U.
112 Clive Cookson, Oxford Nanopore Unveils Mini-DNA Reader, FIN. TIMES (Feb. 17,
2012, 5:09 PM), http://www.ft.com/intl/cms/s/2/318a378a-5900-11e1-b118-00144feabdc0.
html#axzz1oixikxkx.
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remain unsure whether other methods, like full-gene sequencing, would violate
Myriad’s patents on the isolated genes. Some predict that when Myriad’s gene
patents expire, the price of full-genome sequencing will trend as low as $100,
and single-gene test methods will be moot.113
B. Gene Patents Limit Access to Diagnostic Tests
Based on my personal medical history, and my family history of cancer, two
genetic counselors and my oncologist all agreed that I should have Myriad’s . . . test
[from a clinical stand point]. . . .
. . . .
. . . Myriad is the only provider in the country because it has patents on the BRCA
genes, but it will not enter into a contract with my insurance. Myriad holds my fate
and future in its administrative hands, unless of course I am able to pay $3,225 out-
of-pocket. Unfortunately, as a result of my illness and treatment, I do not have an
extra three grand right now.114
Another compelling reason to invalidate Myriad’s patents relates to
patients’ inability to gain access to the BRACAnalysis or BART. This occurs
when patients cannot afford the price of the test, or it is not covered by insur-
ance.115 Both of these administrative complexities create barriers that prevent
access to the latest cancer care options. Consequently, Myriad is able to charge
high rates for its testing, while picking and choosing insurance companies with
which to contract.116 As Myriad remains the United States’ sole provider for
the full BRCA1/2 DNA sequence tests,117 it has complete discretion regarding
these important access decisions.
Myriad Genetics charges approximately $3,000 for their BRCA1/2 diag-
nostic test118 and $700 for their BART test.119 Myriad developed the BART
test separately to test for genetic alterations in the BRCA1/2 genes. Instead of
incorporating BART into BRACAnalysis it is offered separately. Mark Capone,
president of the Myriad laboratory division, said that the company keeps BART
separate because insurers would not pay for it,120 but the company indicates
that it plans to incorporate the BART test into its main product at an unspeci-
fied date.121
113 E.g., Science and Technology, Genes and Patents: More Harm Than Good? Patenting
Genes Is Bad for Diagnosis, ECONOMIST, Apr. 17, 2010, at 90–91.
114 Lisbeth Ceriani, BRCA—Plaintiff Statements, AMERICAN CIVIL LIBERTIES UNION (May
12, 2009), http://www.aclu.org/free-speech_womens-rights/brca-plaintiff-statements#ceriani.
115 Weilbaecher, supra note 17, at 12.
116 See id.
117 See Cook-Deegan et al., supra note 32, at S20.
118 Weilbaecher, supra note 17, at 12.
119 Pollack, supra note 107.
120 Id.
121 See Barbara Puffer, Is Myriad’s Patent on Breast Cancer Genes Valid?, CONNECTICUT
HEALTH I-TEAM (Feb. 16, 2012), http://c-hit.org/2012/02/16/is_myriads_patent_on_breast_
cancer_genes_valid/; see also Turna Ray, Healthcare Providers Petition Myriad to Add
Large Rearrangement Analysis to Standard BRACAnalysis, YALE CANCER GENETIC COUN-
SELING (Aug. 3, 2011), http://yalecancergeneticcounseling.blogspot.com/2011/08/healthcare-
providers-petition-myriad-to_4368.html.
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The ACLU insists that the close relationship between price and utilization
is to blame for those individuals who forgo potentially beneficial tests,122
which can be detrimental to their health. Genetic counselor Ellen Matloff is
similarly concerned; she contends that ninety-five percent of patients she refers
for supplementary testing do not get the test because of its high cost.123 With-
out the ability to pay for another test, Matloff worries about the potential
impact it will have on patients and their relatives since many of these issues are
hereditary. “[F]rom a clinician’s standpoint it is horrifying,” she says.124 Myr-
iad counters this by providing free testing to first-degree relatives when results
are ambiguous.125 However, as Matloff suggests, those affected by hereditary
disease can extend from siblings and children to grandchildren, nieces, and
nephews.126
C. Lacking Competition Diminishes Quality and Efficacy of Tests
Because of patents on the BRCA genes, only one company out there has the
ability to sequence them. I can’t get a second sequencing done at a different company
to validate my results. I am thinking about having my ovaries removed because of
my risk for ovarian cancer. It is uncomfortable making such an important decision
based on only one test.127
One of the derivative problems stemming from Myriad’s monopoly is the
inability for patients to obtain a second opinion or verify their condition if they
receive ambiguous results.128 “There are thousands of mutations along the
BRCA genes and the significance of many of them is unknown. But the gov-
ernment allows Myriad alone to determine which mutations to test for, and to
limit the study of other mutations.”129 Myriad retains complete control over the
data and is under no obligation to share it with other researchers in order to
fully investigate these findings. “Myriad used to share such information with a
public database maintained by the National Institutes of Health, and it cooper-
ated with academic scientists trying to analyze the mutations. But a few years
ago, the company quietly stopped contributing and cooperating, in favor of
building its own database.”130 This raises ethical concerns regarding Myriad’s
behavior in withholding the mutation information. Not only would this infor-
mation be vital for public health initiatives, but some question whether this
extends the monopoly beyond the life of the patent itself.131
Because Myriad does not allow anyone else to review their diagnostic pro-
cedures, women have no way of knowing whether the test was conducted prop-
erly. Similarly, there is no entity that could verify the accuracy of results or
122 See Cook-Deegan et al., supra note 32, at S33.
123 Amanda Wilson, U.S.: ACLU Will Take Gene Patent Case to Supreme Court, INTER
PRESS SERV. (Oct. 14, 2011), http://ipsnews.net/news.asp?idnews=105472.
124 Id. (internal quotation marks omitted).
125 Cook-Deegan et al., supra note 32, at S17.
126 Wilson, supra note 123.
127 Girard, Plaintiff Statement, supra note 25.
128 ACLU FAQ, supra note 13.
129 Id.
130 Pollack, supra note 107.
131 E.g., id.
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perform alternative testing without fear of patent infringement.132 This uncer-
tainty becomes amplified for some minority populations because Myriad’s tests
are more likely to return results for them indicating that they have a “variant of
uncertain significance.”133 Therefore, African-Americans, Hispanics, and
Asian-Americans are at a great disadvantage for cancer treatment options, as
they have no other way to determine if they are at a heightened risk for this
disease.134 This can also lead to psychological confusion for patients, who
already face a great deal of stress given the nature of these diagnostic tests. Elsa
Reich, M.S., is a genetic counselor in New York who provides insight on
resulting difficulties when this situation arises:
Because there is a great burden to patients when there is no answer to the question
“Why?” we as genetics professionals, go to great lengths to find those answers. . . .
When we have only one laboratory that we can use, we have no way of saying
to our patients, “let’s do this a different way”, or “let’s ask someone else.”. . .
. . . I feel that patients deserve the opportunity to benefit from competition; the com-
petition that brings new methods to the testing procedure; the competition that allows
all comers to participate in the research and provide answers to more patients; the
competition that allows for the provision of a second opinion.135
The common perception that Myriad’s exclusivity limits research is a
large concern for many. Specifically, the plaintiffs worry that a lack of compe-
tition does not reassure that Myriad will continue updating its test to reflect the
most current scientific standards, ultimately redirecting the standard of care for
breast cancer testing.136 Dr. Skolnick disagrees, saying the patents’ profitability
actually acts as an incentive to encourage the company to solve any problems
that arise.137 He argues that the limited exclusivity offered by the patent
encourages research and allowed the University of Utah and Myriad Genetics
to develop these tools in the first place.138 BIO agrees, adding that a restriction
on gene patents would actually harm patients because the current system pro-
motes “physician and patient education, broader insurance coverage, and
improved compliance” in the diagnostic field.139
D. Insurance Coverage Challenges
Health insurance providers’ relationships with Myriad Genetics negatively
affect patients’ ability to obtain testing. Women without insurance
(“[n]ationally, 18.8% of women aged 19–64 years are uninsured”140), or with
insurance that does not cover the testing (one study found that 42% of insured
women would not be covered for BRCA1/2 tests141), might not be able to take
132 ACLU FAQ, supra note 13.
133 See id.
134 See id.
135 Elsa Reich, M.S., BRCA—Plaintiff Statements, AMERICAN CIVIL LIBERTIES UNION (May
12, 2009), http://www.aclu.org/free-speech_womens-rights/brca-plaintiff-statements#reich.
136 Declaration of Shobita Parthasarathy, supra note 22, at ¶ 31.
137 Pins, supra note 40, at 382.
138 Weilbaecher, supra note 17, at 11.
139 Id. at 13–14.
140 Cook-Deegan et al., supra note 32, at S33.
141 Id.
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advantage of this “potentially life-saving diagnostic tool.”142 Insurance
problems can arise when Medicaid is involved, when a policy excludes genetic
testing, or if the beneficiary lives in a geographic area where the insurance plan
has strong incentives to minimize utilization.143
Insurance coverage of BRCA1/2 tests has certainly improved since 1995,
when “only 4% of insurance providers . . . had granted coverage of BRCA
testing,”144 but a long road lies ahead as problems within the industry are still
creating obstacles for patients and their families. One study found that only six
percent of decision makers for private health insurance plans would opt to
cover Myriad’s tests if they were made available to all women in the general
population.145 Additionally, only forty-eight percent would offer the tests if
they “were restricted only to women with a positive family history who were
enrolled in an approved research trial.”146 In 2002, another study reported that
only thirty-eight percent of beneficiaries were able to get genetic testing cover-
age from their insurance plan.147
Myriad’s BRACAnalysis website claims that most insurance policies
today cover ninety percent of the costs and reimbursement rates associated with
the test and more than 2,500 payers and health plans have reimbursed testing
with Myriad.148 However, a number of insurers still do not cover BART, and
Myriad has yet to secure Medicare “participating provider” status in twenty-
five states, excluding this entire population from its services.149 In response,
Myriad does offer free testing via financial assistance programs, and they pro-
vide some independent, non-profit institutions with free testing.150 However,
some consequences Myriad cannot fix, like the forty-one percent of women in
2002 who chose not to file an insurance claim despite the fact that ninety-nine
percent of those women had insurance.151 Additionally, fifteen percent of
women in another study chose to self-pay their BRCA1/2 testing fees. Each of
these startling statistics stems from fear of insurance and employment discrimi-
nation, another reality surrounding the BRCA1/2 debate. Myriad says that only
five percent of patients now self-pay, an improvement after the Genetic Infor-
mation Nondiscrimination Act of 2008 (GINA) passed, which helped to reduce
these fears.152
Myriad’s final plea in the insurance challenge is that administration of
BRCA1/2 testing is actually simplified from private insurance contracting
because it relieves patients of the hassle and associated paperwork. The com-
pany also claims that providers benefit too, as Myriad retains all legal liability
for test inaccuracies.153 Additionally, because Myriad is a sole-source provider,
142 Weilbaecher, supra note 17, at 12.
143 Cook-Deegan et al., supra note 32, at S34.
144 Id. at S33.
145 Id.
146 Id.
147 Id.
148 Id.; Conaboy, supra note 35, at 125.
149 Conaboy, supra note 35, at 125–26.
150 Id. at 126.
151 Cook-Deegan et al., supra note 32, at S33.
152 Id.
153 Id.
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it assumes the responsibilities of sample collection, paperwork, and billing that
insurance companies “might otherwise handle at their own institution through
internal billing and administrative procedures.”154 However, these perceived
“advantages” only become available to those insurance companies and benefi-
ciaries that have secured a contract with Myriad in the first place. This creates
an additional burden on patients who learn their condition is not covered by
insurance—a result that comes from Myriad’s exclusivity and choice of insur-
ance contracts.
E. Discord with International Patent Law
Recognition of Myriad’s patents raises disputes of how United States pat-
ents are subsequently treated abroad. Currently there are varying regulations
throughout countries, which in turn create international discrepancies in patent
law, further complicating enforcement strategy in the United States. For exam-
ple, our neighbors in Canada have different public policy that permits labs to
continue testing.155 After receiving various cease-and-desist letters from Myr-
iad Genetics, the Canadian government issued the following statement, “ ‘it is
the government’s position that predictive breast and ovarian cancer tests should
be available to women who require them.’ ”156 In response, Myriad expressed
its surprise that Canada would “continue to provide funding to laboratories that
are directly infringing,” which resulted in a firestorm of media criticism over
Myriad’s bullying tactics.157 Only years later did Myriad give up and redirect
its efforts to building its market in the United States.158 Today, multiple entities
in Canada are able to perform the BRCA1/2 tests because “Canada has not
altered its original position of ignoring not only Myriad’s patents but also the
general issue of the interaction between the human gene patents and the public
health care system.”159 This has ultimately enabled Canadians to access a valu-
able diagnostic tool without restriction and with more competitive pricing.160
Even stricter, China has laws that explicitly oppose one type of human
gene patents for embryonic stem cells, which the United States currently
allows.161 Policy in China takes the same approach in challenging the validity
of stem cell patents as many plaintiffs assume for Myriad’s human gene pat-
ent.162 Chinese law takes into account morality considerations that U.S. patent
law ignores. Rather, in the United States, challengers of stem cell patents argue
that these patents are invalid because they are neither novel nor nonobvious.163
154 Id.
155 E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of the Policy Storm, 12
GENETICS MED. S39, S54 (Apr. 2010 Supp.).
156 Id. at S51.
157 Id. at S52.
158 Id. at S54.
159 Id.
160 Weilbaecher, supra note 17, at 12.
161 Huan Zhu, Comparative Study on Patenting of Human Embryonic Stem Cells, PATENT
DOCS (Nov. 16, 2011), http://www.patentdocs.org/2011/11/comparative-study-on-patenting-
of-human-embryonic-stem-cells.html?utm_source=feedburner&utm_medium=email&utm_
campaign=Feed%3A+PatentDocs+%28Patent+Docs%29.
162 See id.
163 Id.
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Although there are no plans to create a universal patent system, the European
Patent Office, Japan Patent Office, and USPTO recently discussed patent har-
monization strategies at a November 2011 conference.164
In turn, Europe responded strongly to the Myriad litigation as numerous
research institutes and genetics societies filed notices of opposition to Myriad’s
patents.165 There is also substantial speculation surrounding Myriad’s methods
of conducting the full-sequence BRACAnalysis test. A study questioned
whether this was the most cost-effective method. A Lewin Group study sug-
gests that the monopoly is to blame after it found the BRCA1/2 patents to
“affect development and provision of potentially more cost-effective testing
strategies.”166
France echoed this notion, promoting three alternative techniques for
BRCA1/2 diagnosis. One technique, called DDGE (denaturing gradient gel
electrophoresis), “would minimize the cost of diagnosis while also ensuring a
comparable level of effectiveness.”167 Also, when Myriad’s method is com-
pared to a commonly used French testing method, the average cost per detected
mutation was five times higher (this does not even include pricing strategy; it
only focuses on the actual costs entailed to perform the test–supplies, equip-
ment, personnel).168
Further, the Australian government recently made developments in
reviewing its own patent laws.169 Specifically, Australia decided to maintain
genetic material and technology within the scope of its 1990 Patents Act, and is
now reexamining the diagnostic, therapeutic, and surgical treatment method.
Overall, Australia hopes that this technology-neutral approach gives confidence
to biotechnology research and development investments, and “ensure[s] that
patients will not be denied reasonable access to affordable treatments and
essential diagnostic tests” that stem from inappropriate use of patent laws in
Australia.170 The fact that such patents are present in the Australian community
reflects upon the strength of the debate internationally and raises the same
issues being discussed here. Awaiting decision, however, is a 2010 bill, which
would eliminate biological and genetic material patents, but Australians do not
anticipate it will pass: “With the Government response . . . that the Patents Act
should not be amended to explicitly exclude genetic materials from patentabil-
ity, it is difficult to see how the Government could now support that Bill.”171
Perhaps lawmakers in the United States should take a closer look at other
countries for guidance in the Myriad case, both as a matter of public policy and
to examine the realities concerning patent enforcement. Additionally, with
164 Donald Zuhn, USPTO News Briefs: EPO, JPO, and USPTO Meet at Annual Trilateral
Conference, PATENT DOCS (Nov. 17, 2011), http://www.patentdocs.org/2011/11/uspto-news-
briefs-1.html.
165 Weilbaecher, supra note 17, at 12.
166 See Cook-Deegan et al., supra note 32, at S28 (internal quotation marks omitted).
167 Id.
168 Id.
169 Martin O’Brien, News from Abroad: The Gene Patents Debate in Australia—An Update,
PATENT DOCS (Dec. 1, 2011), http://www.patentdocs.org/2011/12/news-from-abroad-the-
gene-patents-debate-in-australia-an-update.html.
170 Id.
171 Id.
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Myriad planning to open a laboratory in Europe sometime next year,172 these
considerations are even more timely.
IV. CONCLUSION
When I was diagnosed with breast cancer, I was only 28. Because I am younger
than most breast cancer patients and because the case was so aggressive, my doctor
recommended that I take the BRCA genetic test to see if I was at higher risk for a
second breast cancer or ovarian cancer.
I took the test but my results were ambiguous. They showed that my BRCA
genes had a “variant of uncertain significance,” indicating that I have a mutation that
may or may not mean a higher risk of cancer. . . .
I will have to make a decision about whether or not to have an oophorectomy
(removal of the ovaries). I’m only 32 and don’t have children. I want to be able to
make an educated decision before I undergo such a serious and life changing
surgery.173
Before Prometheus, gene patent opponents faced an uphill battle. With a
struggling economy and almost thirty years of patent law affirming the patenta-
bility of genes,174 companies like Myriad Genetics have found a lucrative
source of revenue they will fight to protect. Although some legal pundits previ-
ously predicted that the USPTO was not ready to change its standards,175 Pro-
metheus has changed the analytical framework regarding human gene patents.
Myriad Genetics warned of the negative repercussions that would result if
the Court found for the plaintiffs, claiming that the entire foundation of the
biotechnology industry would unravel if human gene patents were invali-
dated.176 This facile argument overlooks the advantages that could result if
other companies were allowed to compete. Most importantly, the cancer
patients who need access to the BRCA1/2 tests would have more affordable
insurance options because more laboratories would offer the test. For individu-
als, like Vicky Thomason, who are unable to pay for the BRCA1/2 tests, and
“get up every day not knowing if [they] have a mutation,”177 this can make an
incredible difference. But, instead of focusing on these objectives, Dr. Skolnick
defends his company against the ACLU and the plaintiffs by saying:
[T]he reason for the bilious attacks against us is that in the past various academic
groups competed with each other on the one hand and various commercial groups
competed with each other on the other hand. There had never previously been com-
petition between a company and more than a dozen academic groups. If research
stays in academia, the same groups which make the discoveries control the funding.
172 Pollack, supra note 107.
173 Runi Limary, BRCA—Plaintiff Statements, AMERICAN CIVIL LIBERTIES UNION (May 12,
2009), http://www.aclu.org/free-speech_womens-rights/brca-plaintiff-statements#limary.
174 Jackson, supra note 4, at 1487.
175 E.g., id. at 1488.
176 See Miri Yoon, Note, Gene Patenting Debate: The Meaning of Myriad, 9 J. MARSHALL
REV. INTELL. PROP. L. 953, 973 (2010).
177 See Vicky Thomason, BRCA—Plaintiff Statements, AMERICAN CIVIL LIBERTIES UNION
(May 12, 2009), http://www.aclu.org/free-speech_womens-rights/brca-plaintiff-statements#
thomason.
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When important research migrates to biotechnology and genomics companies in par-
ticular, the funding is generated outside of academia, and they lose control.178
The possibilities are endless if Myriad’s gene exclusivity ends: researchers
would gain access to valuable data, more efficient testing methods could be
developed, and future developments on the BRCA1/2 genes would not be seen
as patent infringement. For the first time in patent history, the ACLU is ques-
tioning a human gene patent on constitutional grounds:179
The patenting of human genes undermines the free exchange of information and
scientific freedom, bodily integrity, and women’s health. In granting exclusive rights
to gene patent holders, the U.S. government in essence gives patent holders complete
control over those genes and the information contained within them. This interferes
with a person’s right to know about his or her own genetic makeup and scientists’
rights to study the human genome and develop new genetic tests. Granting a monop-
oly on fundamental pieces of knowledge infringes on First Amendment rights, which
protect the freedom of scientific inquiry and the free exchange of knowledge and
ideas.180
The Supreme Court granted certiorari in Myriad for the limited purpose of
vacating and remanding the case for reconsideration in light of Prometheus.181
In Prometheus, the Court reinforced the notion that “laws of nature, natural
phenomena, and abstract ideas” are not patentable, thus fueling the fire against
Myriad. On remand, the Federal Circuit again came out on the wrong side of
the law and science. With a better understanding of the underlying science and
the unrefined patent eligibility standard it set forth in Prometheus, hopefully
the Supreme Court will not let gene patents impede the progress of researchers
and medical professionals seeking to help patients through a better understand-
ing and application of nature’s laws.
178 Declaration of Dr. Mark Skolnick at ¶ 22, Ass’n for Molecular Pathology v. U.S. Patent
& Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010) (No. 09 Civ. 4515 (RWS)).
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a Moment), GENOMICS L. REP. (Mar. 27, 2012), http://www.genomicslawreport.com/index.
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